CureVac Shareholders Approve Landmark BioNTech Acquisition

CureVac investors have officially cleared the path for the company’s acquisition by vaccine developer BioNTech, bringing months of anticipation to a decisive conclusion. During an extraordinary general meeting held this week, shareholders overwhelmingly endorsed the merger agreement, setting the stage for the Tübingen-based firm’s integration into its Mainz-based counterpart.

The voting results demonstrated exceptional investor consensus. An impressive 99.16 percent of participating shareholders approved the public exchange offer, while the legal merger required for structural integration into BioNTech received near-unanimous backing at 99.95 percent. These decisive outcomes remove the primary corporate governance obstacles, effectively finalizing the transaction.

Critical Deadline Approaches for Current Investors

With Read more...